REYKJAVÍK, Iceland; LONDON, United Kingdom — December 22, 2025 — Alvotech has announced the European launch of the world’s first biosimilar to Simponi® (golimumab), commercialized under the brand Gobivaz® (AVT05) by its regional partner Advanz Pharma. The launch, which includes availability in both prefilled syringe and autoinjector presentations, represents a major milestone in the global biosimilars market, supported by early adoption mechanisms including a National Health Service (NHS) England tender award in the United Kingdom .
Science Significance
From a scientific perspective, the introduction of Gobivaz® marks a critical advance in biosimilar monoclonal antibody development. Golimumab is a tumor necrosis factor (TNF) inhibitor used in the treatment of immune-mediated inflammatory diseases, including rheumatoid arthritis and other chronic autoimmune conditions. Approval of AVT05 was supported by a comprehensive comparability program, incorporating analytical characterization, preclinical evaluation, and clinical studies that demonstrated biosimilarity to the reference product in terms of structure, function, pharmacokinetics, and clinical performance. The launch validates Alvotech’s integrated scientific platform for complex biologics and reinforces confidence in the ability of biosimilars to deliver equivalent clinical outcomes to originator biologics.
Regulatory Significance
Regulatorily, the European launch underscores the maturity of the EMA biosimilar framework and the robustness of post-approval cGxP oversight for biologics. As a marketed biosimilar, Gobivaz® enters a lifecycle governed by stringent cGMP manufacturing controls, Qualified Person (QP) batch release, pharmacovigilance obligations, and ongoing comparability commitments. Manufacturing of AVT05 at Alvotech’s Iceland facility highlights the importance of inspection-ready, large-scale biologics production in ensuring consistent quality and supply. The coordinated commercialization with Advanz Pharma further illustrates how partner-based regulatory and quality governance models are executed across multiple European jurisdictions.
Business Significance
Advertisement
From a business standpoint, the launch positions Alvotech as a global leader in first-to-market biosimilars, strengthening its competitive standing in a rapidly expanding sector. Being the first biosimilar entrant to golimumab globally provides a significant early-mover advantage, particularly in tender-driven European healthcare systems. The NHS England tender award establishes a defined pathway for uptake in the UK and signals strong institutional confidence in the product’s quality, value, and supply reliability. For Advanz Pharma, the collaboration reinforces its role as a key commercial partner capable of navigating pricing, reimbursement, and market access across Europe. Together, the companies demonstrate how manufacturing excellence and strategic commercialization translate into sustainable market penetration.
Patients’ Significance
For patients, the availability of Gobivaz® represents a meaningful expansion of access to high-quality biologic therapies. Biosimilars play a critical role in reducing treatment costs while maintaining clinical effectiveness, enabling healthcare systems to treat more patients without compromising outcomes. The NHS-supported introduction in the UK highlights the potential for earlier access, improved continuity of care, and broader prescribing flexibility for clinicians managing chronic inflammatory diseases. Over time, increased biosimilar adoption can also free up healthcare resources, supporting reinvestment into innovative treatments and patient services.
Policy Significance
At the policy level, the launch aligns closely with European and national healthcare priorities aimed at improving biologic medicine affordability and system sustainability. Biosimilars are a cornerstone of policies designed to optimize biologics spending, enhance competition, and ensure long-term supply resilience. The NHS England tender award reflects a policy environment that actively encourages evidence-based biosimilar adoption, supported by regulatory confidence and real-world experience. More broadly, the successful rollout of AVT05 reinforces the role of industrial-scale, cGMP-compliant biologics manufacturing within Europe as a strategic healthcare asset.
Overall, the European launch of Gobivaz® represents a significant convergence of science, regulation, and healthcare policy. By delivering the first biosimilar to golimumab worldwide, Alvotech and Advanz Pharma demonstrate how rigorous biosimilar development, regulatory compliance, and coordinated commercialization can expand patient access to essential biologic medicines. For the cGxP.wire audience, the announcement highlights the growing importance of manufacturing quality, lifecycle compliance, and cross-border regulatory execution in shaping the future of biologics and biosimilars in global healthcare.
Source: Alvotech press release
